本頁面由Tiger Trade Technology Pte. Ltd.提供服務

AN2 Therapeutics, Inc.

5.63
-0.1800-3.10%
成交量:17.14萬
成交額:98.13萬
市值:2.12億
市盈率:-5.41
高:5.82
開:5.82
低:5.59
收:5.81
52周最高:7.19
52周最低:1.00
股本:3,773.62萬
流通股本:1,974.83萬
量比:0.73
換手率:0.87%
股息:- -
股息率:- -
每股收益(TTM):-1.0401
每股收益(LYR):-1.1641
淨資產收益率:-50.12%
總資產收益率:-30.80%
市淨率:2.80
市盈率(LYR):-4.84

資料載入中...

公司資料

公司名字:
AN2 Therapeutics, Inc.
交易所:
NASDAQ
成立時間:
2017
員工人數:
- -
公司地址:
1300 El Camino Real,Suite 100,Menlo Park,California,United States
郵編:
94025
電話:
傳真:
- -
簡介:
AN2 Therapeutics, Inc.於2017年2月24日在特拉華州註冊成立,並於2019年11月開始運營。該公司是一家臨床階段的生物製藥公司,專註於利用其硼化學平台發現和開發新型小分子療法。其研發管線針對血液疾病、感染性疾病和腫瘤學領域。

董事

名稱
職位
Eric Easom
President, Chief Executive Officer, Chair and Director
Gilbert Lynn Marks
Independent Director
Joseph Zakrzewski
Independent Director
Kabeer Aziz
Independent Director
Margaret FitzPatrick
Independent Director
Melvin Spigelman
Independent Director
Patricia Martin
Independent Director
Rob Readnour
Independent Director
Stephanie Wong
Independent Director

股東

名稱
職位
Eric Easom
President, Chief Executive Officer, Chair and Director
Joshua Eizen
Chief Legal Officer and Chief Operating Officer
Lucy Day
Chief Financial Officer
Sanjay Chanda
Chief Development Officer
Sarah Williams
Vice President, Controller and Principal Accounting Officer
Stephen Prior
Chief Strategy Officer